"The launch of PeachesRx is the natural next step in Mangoceuticals' expansion as we continue to redefine direct-to-consumer ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...

Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented ...

Healthcare inflation outpaces CPI due to provider shortages. Find out why income investing ensures steady returns despite ...

Spend billions of dollars to cover anti-obesity drugs under Medicare and Medicaid, or deny more than 7 million people access ...

Applied DNA Sciences exits DNA Tagging business segment. Workforce reduction and GMP site completion announced. Financial results for Q1 fiscal 2025 revealed ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...